FDA OKs first drug made to reduce excessive sweating

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

U.S. regulators on Friday approved the first drug developed specifically to reduce excessive sweating, a common condition that can cause people anxiety and affect their social lives.

The Food and Drug Administration approved Qbrexza for excessive underarm sweating and will be available in October. The drug is inside a cloth wiped over the skin daily to block sweat glands from activating.

Its manufacturer, Dermira Inc., refused to disclose the price, as drugmakers normally do.

An estimated 15.3 million Americans have some form of excessive sweating, but only 1 in 4 get treatment. Current treatment options include Botox injections, surgery to remove sweat glands, procedures using lasers and other devices, and drugs approved for other conditions that block the body’s chemical messengers to reduce sweat production throughout the body.

Side effects of Qbrexza include blurred vision, constipation, burning and itchy skin, head and throat pain, and dry mouth, eyes and skin.

Dermira said in one study, 53 percent of patients reported Qbrexza reduced sweat production by roughly half, versus 28 percent in a comparison group using a nonmedicated cloth.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.